Delivery Order SPE2DB24D2106-SPE2DB25FAVDP

Award Date 4/29/25
Potential Completion Date 4/30/25
Potential Value $40K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is a $22,206.77 firm fixed-price delivery order for the supply of ORENCIA CLICKJECT 125 MG/MLML, a specialized pharmaceutical product. The award is not associated with a set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This federal contract award is a firm fixed-price delivery order worth $58,155.25 issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of ORENCIA CLICKJECT 125 MG/MLML, a specialized pharmaceutical product, to support the medical supply needs of military healthcare facilities. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $39,190.87 firm fixed-price delivery order is for the supply of ORENCIA CLICKJECT 125 MG/ML pharmaceutical products. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the procurement of ORENCIA CLICKJECT 125 MG/ML medication. The contract has a ceiling value of $52,135.44 and a completion date of September 10, 2024. This award is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which has a potential value of...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $23,494.60 firm fixed-price delivery order is for the procurement of 4565829433 ORENCIA CLICKJECT 125 MG/ML. This award is part of a larger single-award indefinite delivery contract (IDC) between DMS Pharmaceutical Group and DLA under the SPE2DB program, valued at up to $499,999,999 and running...
This federal contract award, with ID SPE2DB24D2106|SPE2DB25FAUVF, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $12,210.86 firm fixed-price delivery order is for ORENCIA CLICKJECT 125 MG/MLML, a specialized pharmaceutical product. The contract has an ultimate completion date of March 25, 2025. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award, valued at $30,339.05, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is a firm fixed-price delivery order for ORENCIA CLICKJECT 125 MG/MLML, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract has a ceiling value of $46,215.95 and is a firm fixed-price delivery order for ORENCIA CLICKJECT 125 MG/MLML, a prescription medication. The contract has an ultimate completion date of March 8, 2024. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with...
This federal contract award from the Defense Logistics Agency (DLA) was granted to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $28,761.07 firm fixed-price delivery order is for the supply of ORENCIA CLICKJECT 125 MG/MLML, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $28,240.70 contract is for the provision of Orencia Clickject 125 mg/ml, a specialized pharmaceutical product. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery orders for a comprehensive range of...
  • SPE2DB24D2106
    Indefinite Delivery Contract
  • SPE2DB24D2106-SPE2DB25FAVDP
    Delivery Order

This federal contract award, valued at $39,823.02, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is a delivery order under the DLA's SPE2DB Indefinite Delivery Contract (IDC), which has a ceiling value of $499,999,999 and is valid through November 2026.

The contract is for the delivery of ORENCIA CLICKJECT 125 MG/ML, a pharmaceutical product, with a performance period ending on April 30, 2025. This contract does not have a set-aside designation. DMS Pharmaceutical Group Inc. has a robust portfolio of federal contract awards, primarily focused on supplying a wide range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to military and federal healthcare facilities nationwide.

Generated 7/29/25, 9:52 AM